Arjuna Capital’s United Therapeutics UTHR Stock Holding History

Arjuna Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-662	Closed	-$393K	–	122
2026 Q1	$393K	Buy	662 +18	+3%	+$8.96K	0.1%	97
2025 Q4	$314K	Buy	+644	New	+$300K	0.08%	98

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Arjuna Capital's UTHR Position: Q2 2026 in Review

Arjuna Capital sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 662 shares — an estimated $393K sold.

Arjuna Capital first reported a position in UTHR in Q4 2025 and held it in 2 quarters. The position peaked at $393K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Arjuna Capital reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Arjuna Capital sold 662 United Therapeutics shares in Q2 2026, an estimated $393K.
Arjuna Capital first reported a position in United Therapeutics in Q4 2025 and held it in 2 quarters.
Arjuna Capital's United Therapeutics position peaked at $393K in Q1 2026.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Arjuna Capital's 13F filing for Q2 2026, filed 14 Aug 2026.